AC102-201: A Phase 2 Clinical Trial Comparing the Efficacy of AC102, an Innovative Small Molecule, to Corticosteroids in Patients with Idiopathic Sudden Sensorineural Hearing Loss
Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will present the AC102-201 Phase 2 clinical trial currently underway in 6 European countries comparing the efficacy of AC102 with corticosteroids in the treatment of Sudden Sensorineural Hearing Loss (SSNHL). Dr. Schlingensiepen will also discuss why we urgently need new therapies for SSNHL, especially in light of the new HODOKORT corticosteroid study. (Sun 4th Feb, 8:00 AM, Clinical Podium Session 4)
Efficacy of AC102 in a noise-induced tinnitus model in Mongolian gerbils
For the first time, Dr. Schlingensiepen will present the results of a preclinical proof-of-principle study, testing the efficacy of a single intratympanic AC102 injection for the treatment of acute tinnitus in a noise-induced tinnitus model in Mongolian gerbils. (Mon 5th Feb, 8:00 AM, Tinnitus Podium Session 9)
AC102 Outperforms Dexamethasone in the Treatment of Functional Hearing Loss and Synaptopathy in a Guinea Pig Model of Noise-Induced Hearing Loss
This poster presentation will disclose the latest preclinical results of in-vivo experiments comparing the efficacy of AC102 with dexamethasone, a current standard-of-care treatment for sudden sensorineural hearing loss (SSNHL). In addition, the study compares the effects of AC102 and dexamethasone on outer hair cell loss and synaptopathy in-vivo. (Tue 6th Feb, 1:15-3:15 PM, T77, Poster Session 4)
Contact AudioCure
Frauke Luers